---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-016989"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:51:55.100143+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MAIA activates first U.S. site for Phase 2 THIO-101 trial in advanced NSCLC

## Summary
- First U.S. site activated at Summit Medical Group (NJ); four more U.S. sites planned in 2026.
- 44 active international sites across Europe/Asia; trial evaluates ateganosine as 3L NSCLC therapy.
- $2.3M NIH grant funds third-line evaluation; holds FDA Fast Track designation.
- 2025 data: eight patients with overall survival beyond 2 years, four over 30 months, one at 33 months.
- Approximately 50,000 advanced NSCLC patients in U.S. annually progress to third-line treatment.

## SEC filing metadata
- accession: 0001493152-26-016989
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315226016989/0001493152-26-016989-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315226016989/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-016989
- JSON: https://secwatch.observer/filing/0001493152-26-016989.json
- Plain text: https://secwatch.observer/filing/0001493152-26-016989.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.